However, IFN-β can also have adverse effects (injection site reactions, nausea, headaches, fever, leukopenia, and other more serious although rare) (33); therefore, biomarkers to predict treatment response could avoid these undesirable side effects in patients that may not benefit of the treatment. The gene discussed is IFNB1; the disease is Decreased total leukocyte count.